Dr. Debjit Chattopadhyay is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on gene therapy, immune-oncology, and rare diseases. Prior to joining H.C. Wainwright, Dr. Chattopadhyay has been a Wall Street Healthcare Analyst, on the sell-side, working for Janney Montgomery Scott, Roth Capital Partners, and Boenning & Scattergood. Most recently, Dr. Chattopadhyay worked as the Managing Director and the Head of Biotechnology at Janney Montgomery Scott.
Dr. Chattopadhyay’s educational background includes a Ph.D. from the University of Connecticut and an MBA degree from Drexel University. Dr. Chattopadhyay has also served as an oncology research fellow at Memorial Sloan Kettering Cancer Center.
